Mesoblast Ltd has released a press release.
FDA Supports Accelerated Approval Pathway for Heart Failure
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Earlier from Mesoblast
- MSB Q2 Financial Results and Operational Highlights
- Half Year Financial Results Presentation
- FDA Grants Orphan Drug Designation for Revascor
- FDA Grants Rare Pediatric Disease Designation for Revascor
- Information For Retail Shareholders
Later from Mesoblast
- Mesoblast Completes Placement and Entitlement Offer
- FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
- Mesoblast Resubmits BLA with FDA for Ryoncil Approval
- FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
- Class Action Resolution
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast